Based on the provided information, it appears that Biospecifics is a company that receives a 12.5% royalty on net sales of Xiaflex, a drug used for the treatment of Peyronie’s Disease (PD) and Dupuytren’s Contracture (DC). The drug was marketed by Endo Pharmaceuticals, and the wholesale acquisition cost (WAC) price of Xiaflex is $4,491.
The text also mentions the Cellulite opportunity, where Xiaflex is being explored as a potential pharmacologic therapy for the treatment of cellulite. The filing for a Biologics License Application (BLA) for this indication is expected in the second half of 2019, with approval expected in the second half of 2020. The text mentions that the current approved cellulite therapies are not pharmacologic, and having a noticeable improvement, economical cost, and short recovery time with Xiaflex could be a significant advantage.
Presentation summary generated by ChatGPT